The Filings Report

Boston Scientific Corp.

BSXNYSECIK 885725Healthcare / Medical Devicesfiscal year ends December73 quarters since 2008

Revenue, Q2 FY2026
$5.4B
+7.5% on Q2 FY2025
Net income
$905M
+13.8% on Q2 FY2025
Free cash flow
$1.3B
+13.3% on Q2 FY2025
Diluted EPS
$0.61
+15.1% on Q2 FY2025
Revenue, TTM
$21.0B
trailing four quarters
Net margin, TTM
17.5%
net income $3.7B
Free cash flow, TTM
$3.6B
$4.5B less $904M capex
Cash and equivalents
$539M
long-term debt —, Jun 30, 2026
Shares, 12-month change
−2.2%
1.45B shares, Jun 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Market value
$60.8B
at the close, buybacks

Latest quarter Q2 FY2026, filed August 3, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q2 FY2026, the quarter ended June 30, 2026, Boston Scientific Corp. reported revenue of $5.4B, +7.5% on Q2 FY2025, and net income of $905M (+13.8%). Operating margin was 21.6%. Free cash flow, operating cash flow less capital expenditures, was $1.3B ($1.5B less $195M). Diluted earnings per share were $0.61.

The last 16 quarters

Q3 FY2022 to Q2 FY2026, through the filing of August 3, 2026.

Revenue and net incomeRevenueNet income
$0$2B$4B$6BQ3'22, Revenue: $3.2BQ3'22, Net income: $188MQ3'22Q4'22, Revenue: $3.2BQ4'22, Net income: $140MQ4'22Q1'23, Revenue: $3.4BQ1'23, Net income: $314MQ1'23Q2'23, Revenue: $3.6BQ2'23, Net income: $270MQ2'23Q3'23, Revenue: $3.5BQ3'23, Net income: $504MQ3'23Q4'23, Revenue: $3.7BQ4'23, Net income: $504MQ4'23Q1'24, Revenue: $3.9BQ1'24, Net income: $493MQ1'24Q2'24, Revenue: $4.1BQ2'24, Net income: $322MQ2'24Q3'24, Revenue: $4.2BQ3'24, Net income: $468MQ3'24Q4'24, Revenue: $4.6BQ4'24, Net income: $562MQ4'24Q1'25, Revenue: $4.7BQ1'25, Net income: $672MQ1'25Q2'25, Revenue: $5.1BQ2'25, Net income: $795MQ2'25Q3'25, Revenue: $5.1BQ3'25, Net income: $755MQ3'25Q4'25, Revenue: $5.3BQ4'25, Net income: $670MQ4'25Q1'26, Revenue: $5.2BQ1'26, Net income: $1.3BQ1'26Q2'26, Revenue: $5.4BQ2'26, Net income: $905MQ2'26$0$2B$4B$6BQ3'22, Revenue: $3.2BQ3'22, Net income: $188MQ4'22, Revenue: $3.2BQ4'22, Net income: $140MQ4'22Q1'23, Revenue: $3.4BQ1'23, Net income: $314MQ2'23, Revenue: $3.6BQ2'23, Net income: $270MQ2'23Q3'23, Revenue: $3.5BQ3'23, Net income: $504MQ4'23, Revenue: $3.7BQ4'23, Net income: $504MQ4'23Q1'24, Revenue: $3.9BQ1'24, Net income: $493MQ2'24, Revenue: $4.1BQ2'24, Net income: $322MQ2'24Q3'24, Revenue: $4.2BQ3'24, Net income: $468MQ4'24, Revenue: $4.6BQ4'24, Net income: $562MQ4'24Q1'25, Revenue: $4.7BQ1'25, Net income: $672MQ2'25, Revenue: $5.1BQ2'25, Net income: $795MQ2'25Q3'25, Revenue: $5.1BQ3'25, Net income: $755MQ4'25, Revenue: $5.3BQ4'25, Net income: $670MQ4'25Q1'26, Revenue: $5.2BQ1'26, Net income: $1.3BQ2'26, Revenue: $5.4BQ2'26, Net income: $905MQ2'26

Net income losses drawn in red.

Free cash flow
−$500M$0$500M$1.0B$1.5BQ3'22, Free cash flow: $320MQ3'22Q4'22, Free cash flow: $595MQ4'22Q1'23, Free cash flow: $79MQ1'23Q2'23, Free cash flow: $515MQ2'23Q3'23, Free cash flow: $508MQ3'23Q4'23, Free cash flow: $690MQ4'23Q1'24, Free cash flow: −$15MQ1'24Q2'24, Free cash flow: $658MQ2'24Q3'24, Free cash flow: $823MQ3'24Q4'24, Free cash flow: $1.2BQ4'24Q1'25, Free cash flow: $354MQ1'25Q2'25, Free cash flow: $1.1BQ2'25Q3'25, Free cash flow: $1.2BQ3'25Q4'25, Free cash flow: $1.0BQ4'25Q1'26, Free cash flow: $171MQ1'26Q2'26, Free cash flow: $1.3BQ2'26−$500M$0$500M$1.0B$1.5BQ3'22, Free cash flow: $320MQ4'22, Free cash flow: $595MQ4'22Q1'23, Free cash flow: $79MQ2'23, Free cash flow: $515MQ2'23Q3'23, Free cash flow: $508MQ4'23, Free cash flow: $690MQ4'23Q1'24, Free cash flow: −$15MQ2'24, Free cash flow: $658MQ2'24Q3'24, Free cash flow: $823MQ4'24, Free cash flow: $1.2BQ4'24Q1'25, Free cash flow: $354MQ2'25, Free cash flow: $1.1BQ2'25Q3'25, Free cash flow: $1.2BQ4'25, Free cash flow: $1.0BQ4'25Q1'26, Free cash flow: $171MQ2'26, Free cash flow: $1.3BQ2'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$1B$2B$3BQ3'22, Cash and equivalents: $338MQ3'22Q4'22, Cash and equivalents: $928MQ4'22Q1'23, Cash and equivalents: $570MQ1'23Q2'23, Cash and equivalents: $426MQ2'23Q3'23, Cash and equivalents: $952MQ3'23Q4'23, Cash and equivalents: $865MQ4'23Q1'24, Cash and equivalents: $2.3BQ1'24Q2'24, Cash and equivalents: $2.9BQ2'24Q3'24, Cash and equivalents: $2.5BQ3'24Q4'24, Cash and equivalents: $414MQ4'24Q1'25, Cash and equivalents: $725MQ1'25Q2'25, Cash and equivalents: $534MQ2'25Q3'25, Cash and equivalents: $1.3BQ3'25Q4'25, Cash and equivalents: $2.0BQ4'25Q1'26, Cash and equivalents: $1.5BQ1'26Q2'26, Cash and equivalents: $539MQ2'26$0$1B$2B$3BQ3'22, Cash and equivalents: $338MQ4'22, Cash and equivalents: $928MQ4'22Q1'23, Cash and equivalents: $570MQ2'23, Cash and equivalents: $426MQ2'23Q3'23, Cash and equivalents: $952MQ4'23, Cash and equivalents: $865MQ4'23Q1'24, Cash and equivalents: $2.3BQ2'24, Cash and equivalents: $2.9BQ2'24Q3'24, Cash and equivalents: $2.5BQ4'24, Cash and equivalents: $414MQ4'24Q1'25, Cash and equivalents: $725MQ2'25, Cash and equivalents: $534MQ2'25Q3'25, Cash and equivalents: $1.3BQ4'25, Cash and equivalents: $2.0BQ4'25Q1'26, Cash and equivalents: $1.5BQ2'26, Cash and equivalents: $539MQ2'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q2 FY2026 filed August 3, 2026.

Boston Scientific Corp. income statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 3, 2026Q1 FY2026ended Mar 31, 2026filed May 1, 2026Q4 FY2025ended Dec 31, 2025filed Feb 17, 2026Q3 FY2025ended Sep 30, 2025filed Nov 3, 2025Q2 FY2025ended Jun 30, 2025filed Aug 1, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 18, 2025Q3 FY2024ended Sep 30, 2024filed Nov 1, 2024YoYQ2 FY2026vs Q2 FY2025
Revenue5,4425,2035,2865,0655,0614,6634,5614,209+7.5%
Cost of revenue1,5941,5901,6081,5231,6371,4531,4661,312−2.6%
Gross profit3,8483,6143,6793,5423,4243,2103,0952,897+12.4%
Research and development—————————
Selling, general and administrative1,8031,7811,8341,7411,7161,5971,6121,562+5.1%
Operating income1,1781,1018251,048819921675733+43.8%
Other income (expense)(118)61(125)(110)122(116)(90)(65)−196.7%
Pretax income1,0601,162700939941805585669+12.6%
Income tax155(176)3018314613323200+6.2%
Net income9051,339670755795672562468+13.8%
Diluted EPS ($)0.610.90—0.510.530.45—0.32+15.1%
Diluted shares (millions)1,4751,495—1,4961,4941,493—1,487—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q2 FY2026 filed August 3, 2026.

Boston Scientific Corp. balance sheet, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 3, 2026Q1 FY2026ended Mar 31, 2026filed May 1, 2026Q4 FY2025ended Dec 31, 2025filed Feb 17, 2026Q3 FY2025ended Sep 30, 2025filed Nov 3, 2025Q2 FY2025ended Jun 30, 2025filed Aug 1, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 18, 2025Q3 FY2024ended Sep 30, 2024filed Nov 1, 2024YoYQ2 FY2026vs Q2 FY2025
Cash and equivalents5391,4531,9651,2755347254142,502+0.9%
Short-term investments—————————
Total current assets7,9728,6848,7948,0357,1217,3356,9208,761+12.0%
Total assets45,21644,35143,67342,70741,55940,14039,39538,078+8.8%
Total current liabilities6,4284,5715,4395,3285,1905,0586,3995,910+23.9%
Long-term debt—————————
Total liabilities—————————
Stockholders’ equity25,17226,10424,47223,63022,65322,44622,00320,956+11.1%
Shares outstanding (millions)1,4491,4861,4841,4821,4821,4791,4761,474—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q2 FY2026 filed August 3, 2026.

Boston Scientific Corp. cash flow statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 3, 2026Q1 FY2026ended Mar 31, 2026filed May 1, 2026Q4 FY2025ended Dec 31, 2025filed Feb 17, 2026Q3 FY2025ended Sep 30, 2025filed Nov 3, 2025Q2 FY2025ended Jun 30, 2025filed Aug 1, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 18, 2025Q3 FY2024ended Sep 30, 2024filed Nov 1, 2024YoYQ2 FY2026vs Q2 FY2025
Operating cash flow1,4743481,3641,3431,2865411,4561,002+14.6%
Capital expenditures195177351181157187277179+24.2%
Free cash flow (CFO − capex)1,2791711,0131,1621,1293541,179823+13.3%
Depreciation and amortization355351365342336325348306+5.7%
Share repurchases—————————
Dividends paid——————00—

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 17, 2026.

Income statement

Boston Scientific Corp. income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 17, 2026FY2024ended Dec 31, 2024filed Feb 18, 2025FY2023ended Dec 31, 2023filed Feb 20, 2024FY2022ended Dec 31, 2022filed Feb 23, 2023FY2021ended Dec 31, 2021filed Feb 23, 2022FY2020ended Dec 31, 2020filed Feb 23, 2021FY2019ended Dec 31, 2019filed Feb 25, 2020FY2018ended Dec 31, 2018filed Feb 19, 2019FY2017ended Dec 31, 2017filed Feb 20, 2018FY2016ended Dec 31, 2016filed Feb 23, 2017FY2015ended Dec 31, 2015filed Feb 24, 2016FY2014ended Dec 31, 2014filed Feb 25, 2015FY2013ended Dec 31, 2013filed Feb 26, 2014FY2012ended Dec 31, 2012filed Feb 22, 2013FY2011ended Dec 31, 2011filed Feb 17, 2012FY2010ended Dec 31, 2010filed Feb 17, 2011FY2009ended Dec 31, 2009filed Feb 26, 2010FY2008ended Dec 31, 2008filed Aug 6, 2009FY2007ended Dec 31, 2007filed Aug 6, 2009
Revenue20,07416,74714,24012,68211,8889,91310,7359,8239,0488,3867,4777,4627,0726,9587,6227,8068,1888,0508,357
Cost of revenue6,2215,2574,3453,9563,7113,4653,1162,8132,5932,4242,1732,2102,1742,3492,6592,5992,5762,4692,342
Gross profit13,85411,4909,8968,7278,1776,4487,6207,0116,4555,9625,3045,1704,9694,9004,9635,2075,6125,5816,015
Research and development———————————————————
Selling, general and administrative6,8875,9845,1904,5204,3593,7873,9413,5693,2943,0992,8732,9022,6742,5352,4872,5802,6352,5892,909
Operating income3,6132,6032,3431,6491,199(80)1,5181,5061,285447(283)(301)120(3,868)904(656)(894)(1,505)(14)
Other income (expense)(228)(321)(358)(508)(123)1(831)(85)(353)(270)(367)(208)(343)2219(407)(414)(526)—
Pretax income3,3852,2821,9851,1411,076(79)6871,422933177(650)(509)(223)(4,107)642(1,063)(1,308)(2,031)(569)
Income tax493436393443362(4,013)(249)828(170)(411)(390)(102)(39)2012(283)5(74)
Net income2,8921,8461,5926981,041(82)4,7001,671104347(239)(119)(121)(4,068)441(1,065)(1,025)(2,036)(495)
Diluted EPS ($)1.941.251.070.450.69(0.08)3.331.190.080.25(0.18)(0.09)(0.09)(2.89)0.29(0.70)(0.68)(1.36)(0.33)
Diluted shares (millions)1,4951,4861,4641,4401,4341,4171,4111,4011,3931,3771,3411,3241,3411,4071,5191,5181,5081,4991,487

Balance sheet

Boston Scientific Corp. balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 17, 2026FY2024ended Dec 31, 2024filed Feb 18, 2025FY2023ended Dec 31, 2023filed Feb 20, 2024FY2022ended Dec 31, 2022filed Feb 23, 2023FY2021ended Dec 31, 2021filed Feb 23, 2022FY2020ended Dec 31, 2020filed Feb 23, 2021FY2019ended Dec 31, 2019filed Feb 25, 2020FY2018ended Dec 31, 2018filed Feb 19, 2019FY2017ended Dec 31, 2017filed Feb 20, 2018FY2016ended Dec 31, 2016filed Feb 23, 2017FY2015ended Dec 31, 2015filed Feb 24, 2016FY2014ended Dec 31, 2014filed Feb 25, 2015FY2013ended Dec 31, 2013filed Feb 26, 2014FY2012ended Dec 31, 2012filed Feb 22, 2013FY2011ended Dec 31, 2011filed Feb 17, 2012FY2010ended Dec 31, 2010filed Feb 17, 2011FY2009ended Dec 31, 2009filed Feb 26, 2010FY2008ended Dec 31, 2008filed Aug 6, 2009FY2007ended Dec 31, 2007filed Aug 6, 2009
Cash and equivalents1,9654148659281,9251,7342171461881963195872172072672138641,6411,452
Short-term investments———————————————————
Total current assets8,7946,9206,5145,7606,3176,6944,6994,0033,8223,2393,4713,6063,0113,0223,1053,6154,5995,452—
Total assets43,67339,39535,13632,46932,22930,77730,56520,99919,04218,09618,13317,02416,57117,15421,29022,12825,17727,139—
Total current liabilities5,4396,3994,9333,8034,2743,6814,8665,2605,6543,5872,4302,8461,8241,7721,8072,6093,0223,233—
Long-term debt————————3,8155,4205,6504,2004,2004,2004,2005,450———
Total liabilities———————————————————
Stockholders’ equity24,47222,00319,53017,57316,62215,32613,8778,7267,0126,7336,3206,4576,5396,87011,35311,29612,30113,174—
Shares outstanding (millions)1,4841,4761,4671,4351,4271,4171,3961,3861,3751,3631,3481,3311,3241,3571,4511,5231,511——

Cash flow statement

Boston Scientific Corp. cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 17, 2026FY2024ended Dec 31, 2024filed Feb 18, 2025FY2023ended Dec 31, 2023filed Feb 20, 2024FY2022ended Dec 31, 2022filed Feb 23, 2023FY2021ended Dec 31, 2021filed Feb 23, 2022FY2020ended Dec 31, 2020filed Feb 23, 2021FY2019ended Dec 31, 2019filed Feb 25, 2020FY2018ended Dec 31, 2018filed Feb 19, 2019FY2017ended Dec 31, 2017filed Feb 20, 2018FY2016ended Dec 31, 2016filed Feb 23, 2017FY2015ended Dec 31, 2015filed Feb 24, 2016FY2014ended Dec 31, 2014filed Feb 25, 2015FY2013ended Dec 31, 2013filed Feb 26, 2014FY2012ended Dec 31, 2012filed Feb 22, 2013FY2011ended Dec 31, 2011filed Feb 17, 2012FY2010ended Dec 31, 2010filed Feb 17, 2011FY2009ended Dec 31, 2009filed Feb 26, 2010FY2008ended Dec 31, 2008filed Aug 6, 2009FY2007ended Dec 31, 2007filed Aug 6, 2009
Operating cash flow4,5343,4352,5031,5261,8701,5081,8363101,4261,1826911,2691,1101,2801,0083258351,216934
Capital expenditures876790711588554376461316319376247259245226304272312362363
Free cash flow (CFO − capex)3,6582,6451,7929381,3161,1321,375(6)1,1078064441,0108651,05470453523854571
Depreciation and amortization1,3681,2691,1961,1361,0931,1231,011894844815769725689683717816834864918
Share repurchases———0053500—00125500600492————
Dividends paid—02855552800———————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$9M
5 purchases by 3 insiders; officers and directors $9M
Sold, three months
$0
0 sales by 0 insiders; officers and directors $0
Bought, twelve months
$10M
10 purchases by 5 insiders; officers and directors $10M
Sold, twelve months
$23M
7 sales by 4 insiders; officers and directors $23M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Sep 2, 2026O'Connor Padraig AndrewEVP, Global Operationsoption exercise1,171$0.00—8,459Sep 3, 2026
Sep 2, 2026O'Connor Padraig AndrewEVP, Global Operationstax withholding567$48.37$27K7,892Sep 3, 2026
Aug 25, 2026Morano Susan EDirectoropen-market buy2,040$49.22$100K13,784Aug 26, 2026
Aug 11, 2026Woodworth EmilySVP, Global Controller and CAOdiscretionaryindirect2,930$51.19$150K2,930Aug 12, 2026
Aug 10, 2026Monson JonathanEVP and CFOdiscretionaryindirect9,908$50.46$500K9,908Aug 11, 2026
Aug 5, 2026Habiger David CDirectoropen-market buy2,100$47.59$100K17,160Aug 7, 2026
Aug 4, 2026Habiger David CDirectoropen-market buy140$48.59$7K15,060Aug 5, 2026
Aug 3, 2026Habiger David CDirectoropen-market buy1,042$48.07$50K14,920Aug 5, 2026
Aug 3, 2026Mahoney Michael FChairman, President & CEO, Directoropen-market buy186,240$48.33$9M2MAug 5, 2026
Aug 3, 2026Mahoney Michael FChairman, President & CEO, Directordiscretionaryindirect22,119$48.43$1M22,119Aug 5, 2026
Jul 31, 2026Ludwig Edward JDirectoropen-market buy5,000$45.48$227K30,359Aug 3, 2026
Jul 31, 2026Fitzgerald Joseph MichaelEVP & Group Pres, Cardiologydiscretionaryindirect64,198$46.73$3M64,198Aug 3, 2026
Jul 1, 2026Monson JonathanEVP and CFOoption exercise2,087$0.00—40,073Jul 2, 2026
Jul 1, 2026Monson JonathanEVP and CFOtax withholding1,010$43.06$43K39,063Jul 2, 2026
May 28, 2026Mahoney Michael FChairman, President & CEO, Directorgiftindirect386,755$0.00—0Jun 1, 2026
May 20, 2026Pegus CherylDirectoropen-market buy1,770$56.49$100K1,770May 21, 2026
May 20, 2026Ludwig Edward JDirectoropen-market buy3,580$56.68$203K25,359May 21, 2026
May 20, 2026Habiger David CDirectoropen-market buy2,250$55.92$126K13,878May 21, 2026
May 19, 2026Habiger David CDirectoropen-market buy2,200$56.95$125K11,628May 21, 2026
May 7, 2026Zane Ellen MDirectoraward3,800$0.00—27,934May 11, 2026
May 7, 2026Wichmann David SDirectoraward3,800$0.00—45,382May 11, 2026
May 7, 2026Weber Christophe PierreDirectoraward1,767$0.00—2,646May 11, 2026
May 7, 2026Weber Christophe PierreDirectoraward1,140$0.00—3,786May 11, 2026
May 7, 2026Morano Susan EDirectoraward3,800$0.00—10,463May 11, 2026
May 7, 2026Morano Susan EDirectoraward1,281$0.00—11,744May 11, 2026

Full insider history for Boston Scientific Corp., or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
BOSTON SCIENTIFIC CORPORATION, CIK 885725 on EDGAR
Extract generated
August 27, 2026
Withheld
1 line-years whose four quarters do not sum to the filed year: revenue FY2015
Repaired
1 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: net income FY2017
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues, SalesRevenueNet
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: GrossProfit
Research and development: not filed
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense, OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: ProfitLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: not filed
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt
Total liabilities: not filed
Stockholders’ equity: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationAndAmortization, DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividends

The data

The statements on this page as files, generated August 27, 2026.

JSON file
/data/financials/BSX.json